% | $
Quotes you view appear here for quick access.

RXi Pharmaceuticals Corporation Message Board

  • c.eastwood39 c.eastwood39 Mar 16, 2013 9:16 AM Flag

    here's the problem

    ---------- "The utility of RNAi technology is severely limited by limited availability of efficient delivery of RNAi compounds to primary cells and in vivo." ----------

    You mupps better find out about Advirna LLC run by Alexey D. and his partner Anastasia Khvorova.

    "sdRNA" and "rxRNA"?

    I see Tod Woolf is still in the picture. HO HO HO

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ROCHE is the biggest Pharma in the world. Investigate what they concluded about RNAi "delivery". Hint: they spent over $400 million

      Hint Hint: They discarded their RNAi program.

      Sentiment: Sell

    • casserta Mar 27, 2013 9:05 AM Flag

      Somebody tell red to hire a tutor and take Biology 101 and buy "Investing for Dummies"

      Sentiment: Strong Sell

    • on top!

    • Thanks, clint.


    • Could it be that your DD is full of holes parallel with your cheese brain ?

      RXi has contributed a major advance to the RNAi field with its self-delivering RNAi technology. This technology overcomes******************* a major delivery obstacle of prior RNAi technologies by significantly enhancing the uptake of the gene-targeting drug into cells.************************ We also are impressed with RXi’s development capabilities, as evidenced by its rapid advancement of RXI-109, an exciting product candidate for the potential treatment of dermal scarring.”

    • RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. In 2006, Andrew Fire and Craig C. Mello shared the Nobel Prize in Physiology or Medicine for their work on RNA interference in the nematode worm C. elegans, which they published in 1998.

      Two types of small ribonucleic acid (RNA) molecules – microRNA (miRNA) and small interfering RNA (siRNA) – are central to RNA interference. RNAs are the direct products of genes, and these small RNAs can bind to other specific messenger RNA (mRNA) molecules and either increase or decrease their activity, for example by preventing an mRNA from producing a protein. RNA interference has an important role in defending cells against parasitic nucleotide sequences – viruses and transposons – but also in directing development as well as gene expression in general.

      The RNAi pathway is found in many eukaryotes including animals and is initiated by the enzyme Dicer, which cleaves long double-stranded RNA (dsRNA) molecules into short double stranded fragments of ~20 nucleotides that are called siRNAs. Each siRNA is unwound into two single-stranded (ss) ssRNAs, namely the passenger strand and the guide strand. The passenger strand is degraded, and the guide strand is incorporated into the RNA-induced silencing complex (RISC). The most well-studied outcome is post-transcriptional gene silencing, which occurs when the guide strand base pairs with a complementary sequence in a messenger RNA molecule and induces cleavage by Argonaute, the catalytic component of the RISC complex. In some organisms, this process is known to spread systemically, despite the initially limited molar concentrations of siRNA.

      RNAi has become a valuable research tool, both in cell culture and in living organisms, because synthetic dsRNA introduced into cells can selectively and robustly induce suppression of specific genes of interest. RNAi may be used for large-scale screens that systematically shut down each gene in the cell, which can help identify the components necessary for a particular cellular process or an event such as cell division. The pathway is also used as a practical tool in biotechnology and medicine.

    • If we follow your limited thought we would be still living in a cavern.

      Sentiment: Strong Buy

2.22+0.05(+2.30%)1:45 PMEDT